Green Cross
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pert… Read more
Green Cross (005250) - Net Assets
Latest net assets as of September 2025: ₩1.89 Trillion KRW
Based on the latest financial reports, Green Cross (005250) has net assets worth ₩1.89 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩4.28 Trillion) and total liabilities (₩2.40 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.89 Trillion |
| % of Total Assets | 44.01% |
| Annual Growth Rate | 8.16% |
| 5-Year Change | 10.68% |
| 10-Year Change | 41.67% |
| Growth Volatility | 19.14 |
Green Cross - Net Assets Trend (2000–2024)
This chart illustrates how Green Cross's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Green Cross (2000–2024)
The table below shows the annual net assets of Green Cross from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.85 Trillion | -1.56% |
| 2023-12-31 | ₩1.88 Trillion | -4.35% |
| 2022-12-31 | ₩1.97 Trillion | +2.95% |
| 2021-12-31 | ₩1.91 Trillion | +14.18% |
| 2020-12-31 | ₩1.67 Trillion | +11.08% |
| 2019-12-31 | ₩1.51 Trillion | +3.68% |
| 2018-12-31 | ₩1.45 Trillion | +0.93% |
| 2017-12-31 | ₩1.44 Trillion | +4.55% |
| 2016-12-31 | ₩1.38 Trillion | +5.33% |
| 2015-12-31 | ₩1.31 Trillion | +10.69% |
| 2014-12-31 | ₩1.18 Trillion | +7.40% |
| 2013-12-31 | ₩1.10 Trillion | +13.04% |
| 2012-12-31 | ₩972.83 Billion | +8.60% |
| 2011-12-31 | ₩895.76 Billion | +6.66% |
| 2010-12-31 | ₩839.83 Billion | +60.65% |
| 2009-12-31 | ₩522.78 Billion | +49.16% |
| 2008-12-31 | ₩350.47 Billion | -0.17% |
| 2007-12-31 | ₩351.08 Billion | +58.34% |
| 2006-12-31 | ₩221.73 Billion | -6.43% |
| 2005-12-31 | ₩236.96 Billion | +12.82% |
| 2004-12-31 | ₩210.03 Billion | -0.09% |
| 2003-12-31 | ₩210.22 Billion | -3.94% |
| 2002-12-31 | ₩218.85 Billion | -20.11% |
| 2001-12-31 | ₩273.93 Billion | -2.91% |
| 2000-12-31 | ₩282.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 89682049545000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩896.82 Billion | 90.22% |
| Other Components | ₩97.27 Billion | 9.78% |
| Total Equity | ₩994.09 Billion | 100.00% |
Green Cross Competitors by Market Cap
The table below lists competitors of Green Cross ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ji'an Mankun Technology Co. Ltd. A
SHE:301132
|
$228.92 Million |
|
METALL ZUG AG Part. Cert.
LSE:0QLX
|
$228.96 Million |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
$228.96 Million |
|
Shanxi Yongdong Chemistry Industry Co Ltd
SHE:002753
|
$228.99 Million |
|
Northern Arc Capital Ltd
NSE:NORTHARC
|
$228.80 Million |
|
Jintuo Technology Co Ltd
SHG:603211
|
$228.78 Million |
|
Daihatsu Diesel Mfg. Co. Ltd
F:D1U
|
$228.76 Million |
|
Zhejiang Tiantai Xianghe Industrial Co Ltd
SHG:603500
|
$228.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 980,252,078,600 to 994,091,218,410, a change of 13,839,139,810 (1.4%).
- Net income of 24,025,031,680 contributed positively to equity growth.
- Dividend payments of 25,432,020,640 reduced retained earnings.
- New share issuances of 12,131,243,500 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩24.03 Billion | +2.42% |
| Dividends Paid | ₩25.43 Billion | -2.56% |
| Share Issuances | ₩12.13 Billion | +1.22% |
| Other Changes | ₩3.11 Billion | +0.31% |
| Total Change | ₩- | 1.41% |
Book Value vs Market Value Analysis
This analysis compares Green Cross's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.78x to 0.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩18088.90 | ₩14040.00 | x |
| 2018-12-31 | ₩17900.56 | ₩14040.00 | x |
| 2019-12-31 | ₩18089.53 | ₩14040.00 | x |
| 2020-12-31 | ₩20458.83 | ₩14040.00 | x |
| 2021-12-31 | ₩22820.59 | ₩14040.00 | x |
| 2022-12-31 | ₩23094.53 | ₩14040.00 | x |
| 2023-12-31 | ₩21815.28 | ₩14040.00 | x |
| 2024-12-31 | ₩22123.27 | ₩14040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.09%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 3.69x
- Recent ROE (2.42%) is below the historical average (6.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 19.53% | 19.49% | 0.63x | 1.59x | ₩25.92 Billion |
| 2001 | 2.60% | 2.18% | 0.56x | 2.12x | ₩-17.10 Billion |
| 2002 | 5.45% | 2.99% | 0.81x | 2.26x | ₩-8.19 Billion |
| 2003 | 2.14% | 0.65% | 0.35x | 9.44x | ₩-13.36 Billion |
| 2004 | 0.55% | 0.12% | 0.47x | 9.67x | ₩-15.84 Billion |
| 2005 | 2.93% | 0.61% | 0.47x | 10.06x | ₩-12.40 Billion |
| 2006 | 4.01% | 0.66% | 0.46x | 13.19x | ₩-9.14 Billion |
| 2007 | 11.36% | 2.15% | 0.47x | 11.33x | ₩2.92 Billion |
| 2008 | 9.79% | 1.72% | 0.44x | 12.87x | ₩-458.64 Million |
| 2009 | 12.09% | 2.45% | 0.46x | 10.82x | ₩6.45 Billion |
| 2010 | 12.06% | 3.76% | 0.44x | 7.37x | ₩11.50 Billion |
| 2011 | 4.91% | 3.36% | 0.18x | 8.23x | ₩-28.47 Billion |
| 2012 | 9.85% | 7.15% | 0.59x | 2.33x | ₩-954.19 Million |
| 2013 | 6.42% | 4.61% | 0.58x | 2.41x | ₩-24.07 Billion |
| 2014 | 8.03% | 5.42% | 0.58x | 2.54x | ₩-13.88 Billion |
| 2015 | 8.95% | 5.77% | 0.55x | 2.82x | ₩-7.67 Billion |
| 2016 | 6.11% | 3.48% | 0.60x | 2.92x | ₩-29.98 Billion |
| 2017 | 5.34% | 2.96% | 0.57x | 3.15x | ₩-37.92 Billion |
| 2018 | 2.30% | 1.19% | 0.59x | 3.27x | ₩-61.97 Billion |
| 2019 | 0.36% | 0.19% | 0.55x | 3.41x | ₩-78.33 Billion |
| 2020 | 18.60% | 9.94% | 0.53x | 3.53x | ₩79.03 Billion |
| 2021 | 5.39% | 3.00% | 0.53x | 3.41x | ₩-47.27 Billion |
| 2022 | 3.16% | 1.58% | 0.58x | 3.46x | ₩-70.95 Billion |
| 2023 | -5.52% | -2.63% | 0.55x | 3.81x | ₩-152.16 Billion |
| 2024 | 2.42% | 1.09% | 0.60x | 3.69x | ₩-75.38 Billion |
Industry Comparison
This section compares Green Cross's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,639,101,868
- Average return on equity (ROE) among peers: -13.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross (005250) | ₩1.89 Trillion | 19.53% | 1.27x | $228.88 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |